GAS-BASED DRUG ADMINISTRATION SYSTEMS FOR PATIENT TREATMENT

Abstract

ABSTRACT GAS-BASED DRUG ADMINISTRATION SYSTEMS FOR PATIENT TREATMENT The present disclosure introduces a gas-based drug administration system for patient treatment 100, designed for efficient delivery of therapeutic agents. The system comprises gas source 102 supplying medical-grade gases and drug delivery module 104 mixing the therapeutic agent with the gas to create a uniform gas-drug mixture. A control unit 106 regulates flow rate and dosage, while aerosolization technology 110 ensures uniform particle dispersion. The administration interface 108 delivers the mixture, and real-time feedback mechanism 138 monitors patient vitals to dynamically adjust parameters via an adaptive drug release profile system 114. The system incorporates telehealth integration 116 for remote monitoring, AI-powered predictive analytics 140 for data-driven treatment optimization, and cloud-based data storage and analysis 146 for long-term access. Additional features are emergency override functionality 128, quality control system 130, and wearable device connectivity 122 for enhanced personalization and safety. Reference fig 1

Specification

Description:Gas-Based Drug Administration Systems for Patient Treatment
TECHNICAL FIELD
[0001] The present innovation relates to gas-based drug administration systems designed for precise, controlled delivery of therapeutic agents to patients.

BACKGROUND

[0002] The administration of therapeutic agents is a critical aspect of modern medicine, but traditional methods like oral, intravenous (IV), and intramuscular delivery have significant limitations. Oral administration often results in inconsistent absorption due to variations in gastrointestinal conditions, such as pH and food presence, which can compromise therapeutic efficacy. IV and intramuscular injections, though effective, pose risks of infection, require skilled personnel, and can cause discomfort, anxiety, and inconvenience to patients. These challenges often lead to poor patient compliance, undermining treatment success. Existing alternatives, such as inhalation therapies and gaseous anesthetics, are primarily limited to specific applications like respiratory conditions and lack the versatility to accommodate a wide range of therapeutic agents or provide targeted delivery for systemic and localized treatments.

[0003] The invention of a gas-based drug administration system addresses these limitations by utilizing gases as a medium for precise and controlled drug delivery. Unlike traditional methods, this system leverages the rapid diffusion and transport properties of gases to enhance the efficacy of drug delivery, enabling both systemic and localized administration. Its novel design allows for the integration of diverse therapeutic agents, including small molecules, biologics, and nanoparticles, which can be delivered in a non-invasive and patient-friendly manner. The invention incorporates advanced features such as real-time dosage control, adaptive drug release profiles, and compatibility with telehealth systems for remote monitoring and adjustments.
[0004] By offering a customizable, efficient, and sustainable approach, this system overcomes the drawbacks of existing options, ensuring higher patient comfort, improved adherence to treatment, and reduced systemic exposure to drugs. The modular and environmentally sustainable design further differentiates this invention, making it a groundbreaking advancement in drug delivery technology. Its novelty lies in its ability to combine precision, versatility, and adaptability, revolutionizing patient care across various medical disciplines.

OBJECTS OF THE INVENTION

[0005] The primary object of the invention is to provide a precise and controlled gas-based drug administration system for improved therapeutic outcomes.

[0006] Another object of the invention is to enhance patient comfort by offering a non-invasive drug delivery method, reducing the anxiety and pain associated with injections.

[0007] Another object of the invention is to improve treatment efficacy by enabling targeted and localized delivery of therapeutic agents, minimizing systemic side effects.

[0008] Another object of the invention is to offer versatility by accommodating a wide range of therapeutic agents, including small molecules, biologics, and nanoparticles.

[0009] Another object of the invention is to optimize drug usage and reduce waste through advanced dosage control and real-time monitoring features.

[00010] Another object of the invention is to integrate seamlessly with telehealth systems, enabling remote monitoring, adjustments, and proactive patient management.

[00011] Another object of the invention is to enhance safety by incorporating features like pressure regulation, adaptive feedback mechanisms, and emergency override functionality.

[00012] Another object of the invention is to promote sustainability through the use of refillable gas cartridges and environmentally friendly materials, aligning with global sustainability goals.

[00013] Another object of the invention is to support personalized medicine by allowing customization of therapy protocols based on individual patient needs and conditions.

[00014] Another object of the invention is to advance healthcare innovation by providing a modular, adaptable system that integrates easily with existing medical devices and clinical workflows.

SUMMARY OF THE INVENTION

[00015] In accordance with the different aspects of the present invention, gas based drug administration systems for patient treatment is presented. The invention relates to a gas-based drug administration system designed for precise and controlled delivery of therapeutic agents. It leverages gases as a medium to enhance drug transport, enabling both systemic and localized treatments with reduced side effects. The system features advanced dosage control, real-time monitoring, and adaptability for diverse therapeutic agents. Its non-invasive, patient-friendly design promotes comfort and adherence to treatment protocols. Additionally, the invention supports sustainability and integration with telehealth systems, revolutionizing modern drug delivery methods.
[00016] Additional aspects, advantages, features and objects of the present disclosure would be made apparent from the drawings and the detailed description of the illustrative embodiments constructed in conjunction with the appended claims that follow.

[00017] It will be appreciated that features of the present disclosure are susceptible to being combined in various combinations without departing from the scope of the present disclosure as defined by the appended claims.

BRIEF DESCRIPTION OF DRAWINGS
[00018] The summary above, as well as the following detailed description of illustrative embodiments, is better understood when read in conjunction with the appended drawings. For the purpose of illustrating the present disclosure, exemplary constructions of the disclosure are shown in the drawings. However, the present disclosure is not limited to specific methods and instrumentalities disclosed herein. Moreover, those in the art will understand that the drawings are not to scale. Wherever possible, like elements have been indicated by identical numbers.

[00019] Embodiments of the present disclosure will now be described, by way of example only, with reference to the following diagrams wherein:

[00020] FIG. 1 is component wise drawing for gas based drug administration systems for patient treatment.

[00021] FIG 2 is working methodology of gas based drug administration systems for patient treatment.

DETAILED DESCRIPTION

[00022] The following detailed description illustrates embodiments of the present disclosure and ways in which they can be implemented. Although some modes of carrying out the present disclosure have been disclosed, those skilled in the art would recognise that other embodiments for carrying out or practising the present disclosure are also possible.

[00023] The description set forth below in connection with the appended drawings is intended as a description of certain embodiments of gas based drug administration systems for patient treatment and is not intended to represent the only forms that may be developed or utilised. The description sets forth the various structures and/or functions in connection with the illustrated embodiments; however, it is to be understood that the disclosed embodiments are merely exemplary of the disclosure that may be embodied in various and alternative forms. The figures are not necessarily to scale; some features may be exaggerated or minimised to show details of particular components. Therefore, specific structural and functional details disclosed herein are not to be interpreted as limiting, but merely as a representative basis for teaching one skilled in the art to variously employ the present invention.

[00024] While the disclosure is susceptible to various modifications and alternative forms, specific embodiment thereof has been shown by way of example in the drawings and will be described in detail below. It should be understood, however, that it is not intended to limit the disclosure to the particular forms disclosed, but on the contrary, the disclosure is to cover all modifications, equivalents, and alternatives falling within the scope of the disclosure.

[00025] The terms "comprises", "comprising", "include(s)", or any other variations thereof, are intended to cover a non-exclusive inclusion, such that a setup, or system that comprises a list of components or steps does not include only those components or steps but may include other components or steps not expressly listed or inherent to such setup or system. In other words, one or more elements in a system or apparatus preceded by "comprises... a" does not, without more constraints, preclude the existence of other elements or additional elements in the system or apparatus.

[00026] In the following detailed description of the embodiments of the disclosure, reference is made to the accompanying drawings and which are shown by way of illustration-specific embodiments in which the disclosure may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the disclosure, and it is to be understood that other embodiments may be utilized and that changes may be made without departing from the scope of the present disclosure. The following description is, therefore, not to be taken in a limiting sense.

[00027] The present disclosure will be described herein below with reference to the accompanying drawings. In the following description, well-known functions or constructions are not described in detail since they would obscure the description with unnecessary detail.

[00028] Referring to Fig. 1, gas based drug administration systems for patient treatment 100 is disclosed in accordance with one embodiment of the present invention. It comprises of gas source 102, drug delivery module 104, control unit 106, administration interface 108, aerosolization technology 110, safety mechanisms 112, adaptive drug release profile system 114, telehealth integration 116, user interface 118, data analytics and reporting system 120, wearable device connectivity 122, modular architecture 124, environmentally sustainable features 126, emergency override functionality 128, quality control system 130, patient-specific calibration 132, gas-drug mixture optimization technology 134, interchangeable administration interfaces 136, real-time feedback mechanism 138, ai-powered predictive analytics 140, integrated patient education resources 142, enhanced aerosolization techniques 144, cloud-based data storage and analysis 146, multifunctional treatment applications 148, cross-compatibility with existing medical devices 150, user feedback loop for continuous improvement 152.

[00029] Referring to Fig. 1, the present disclosure provides details of gas based drug administration systems for patient treatment 100. It is an innovative system designed to deliver therapeutic agents precisely and efficiently using gases as a carrier medium. It enables controlled and targeted drug delivery, enhancing treatment efficacy while minimizing side effects. In one of the embodiments, the gas-based drug administration system 100 may be provided with the following key components such as gas source 102, drug delivery module 104, and control unit 106, facilitating precise drug formulation and delivery. The system incorporates administration interface 108 and aerosolization technology 110 to ensure optimal distribution and absorption. It also features adaptive drug release profile system 114 and data analytics and reporting system 120 for personalized treatment and real-time monitoring. Additional components such as emergency override functionality 128 and cloud-based data storage and analysis 146 enhance safety, accessibility, and data-driven decision-making.

[00030] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with gas source 102, which supplies medical-grade gases such as oxygen, nitrous oxide, or other suitable gases as a carrier medium for therapeutic agents. The gas source 102 ensures a consistent and controlled supply of gas to the drug delivery module 104 for precise formulation. It works in conjunction with the control unit 106 to regulate the flow rate and pressure, ensuring optimal conditions for drug administration. The gas source 102 plays a critical role in maintaining the stability and efficacy of the gas-drug mixture during delivery.

[00031] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with drug delivery module 104, which formulates and mixes therapeutic agents with the gas from the gas source 102. The module uses technologies like nebulizers or atomizers to create a uniform mixture for delivery. It interacts closely with the control unit 106, which adjusts the dosage and flow based on patient requirements. The drug delivery module 104 ensures the therapeutic agent is dispersed in optimal concentrations for systemic or localized administration via the administration interface 108.

[00032] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with control unit 106, which governs the operation of other components, including the gas source 102 and drug delivery module 104. It features programmable settings for adjusting dosage, flow rate, and delivery duration. The control unit 106 works with the real-time feedback mechanism 138 to adapt parameters based on patient responses. Its seamless integration with the data analytics and reporting system 120 ensures effective monitoring and customization of drug delivery.

[00033] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with administration interface 108, which delivers the gas-drug mixture to the patient. It comprises interchangeable interfaces like masks, nasal cannulas, or catheters to cater to various treatment needs. The administration interface 108 works closely with the drug delivery module 104 to ensure the proper dispersion of the therapeutic agent. Its compatibility with wearable device connectivity 122 enables real-time monitoring of patient vitals during treatment.

[00034] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with aerosolization technology 110, which ensures the uniform distribution of therapeutic agents within the gas medium. The technology creates particles of optimal size for targeted delivery to specific tissues. It works synergistically with the drug delivery module 104 and administration interface 108 to enhance absorption and efficacy. The aerosolization technology 110 also integrates with the adaptive drug release profile system 114 for dynamic adjustment of drug delivery rates based on patient conditions.

[00035] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with safety mechanisms 112, which comprises features such as pressure regulation, automatic shut-off, and alarms for abnormal conditions. These mechanisms ensure the safe operation of the gas source 102 and drug delivery module 104 during administration. The safety mechanisms 112 work in conjunction with the control unit 106 to respond to system malfunctions or deviations from prescribed settings. They are critical for maintaining patient safety and preventing accidents during drug delivery.

[00036] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with adaptive drug release profile system 114, which dynamically modifies the rate of drug delivery based on patient feedback and real-time data. The system integrates with the control unit 106 and real-time feedback mechanism 138 to adjust flow rates and dosages in response to physiological changes. The adaptive drug release profile system 114 ensures personalized treatment, improving therapeutic outcomes and minimizing side effects.

[00037] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with telehealth integration 116, which enables remote monitoring and management of drug delivery through digital platforms. This feature allows healthcare providers to access data from the control unit 106 and data analytics and reporting system 120 for proactive adjustments to treatment. Telehealth integration 116 supports enhanced accessibility, especially for patients in remote locations, and promotes better continuity of care.

[00038] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with user interface 118, which offers an intuitive touchscreen or mobile application for monitoring and controlling the system. The interface allows users to adjust settings of the control unit 106, view real-time data from the data analytics and reporting system 120, and access tutorials or treatment reminders. The user interface 118 improves usability, patient compliance, and healthcare provider efficiency.

[00039] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with data analytics and reporting system 120, which collects, analyzes, and stores data on treatment efficacy and patient responses. This system works closely with the real-time feedback mechanism 138 to provide actionable insights for healthcare providers. Data analytics and reporting system 120 also integrates with cloud-based data storage and analysis 146 for remote access and collaborative decision-making.

[00040] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with wearable device connectivity 122, which links the system with devices like smartwatches and fitness trackers. This connectivity allows the system to monitor vital signs and patient activity levels in real time. Wearable device connectivity 122 collaborates with the control unit 106 and telehealth integration 116 to ensure continuous and informed treatment adjustments.

[00041] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with modular architecture 124, which allows for easy upgrades and customization of the system to meet emerging medical needs. This architecture supports seamless integration with components like gas source 102 and drug delivery module 104, extending the system's lifecycle and versatility. Modular architecture 124 ensures adaptability for various clinical applications and technologies.

[00042] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with environmentally sustainable features 126, which comprises refillable gas cartridges and biodegradable materials. These features reduce medical waste and promote responsible use of resources. Environmentally sustainable features 126 are designed to work with other components such as the gas source 102 and drug delivery module 104 without compromising functionality.

[00043] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with emergency override functionality 128, which allows for immediate cessation of drug delivery in critical situations. This functionality interacts with the control unit 106 and safety mechanisms 112 to enhance patient safety during unexpected events. Emergency override functionality 128 ensures quick response to emergencies, preventing potential harm.

[00044] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with quality control system 130, which continuously assesses the integrity and consistency of the gas-drug mixture. This system works with the drug delivery module 104 and aerosolization technology 110 to maintain delivery standards. The quality control system 130 ensures reliable and effective treatments, reducing the risk of ineffective dosages.

[00045] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with patient-specific calibration 132, which adjusts drug dosages based on factors such as age, weight, and metabolic rate. This calibration integrates with the adaptive drug release profile system 114 and control unit 106 to deliver personalized treatment. Patient-specific calibration 132 improves therapeutic precision and reduces the risk of over- or under-dosage.

[00046] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with gas-drug mixture optimization technology 134, which uses advanced algorithms to balance the ratio of gas to therapeutic agent. This technology works in conjunction with the drug delivery module 104 and control unit 106 to ensure optimal efficacy. Gas-drug mixture optimization technology 134 minimizes side effects and enhances treatment outcomes.

[00047] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with interchangeable administration interfaces 136, which comprises various delivery options like masks, nasal cannulas, and catheters. These interfaces collaborate with the drug delivery module 104 and aerosolization technology 110 to ensure flexibility in drug delivery methods. Interchangeable administration interfaces 136 cater to both systemic and localized treatments.
[00048] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with real-time feedback mechanism 138, which monitors patient responses such as oxygen saturation and vital signs. This mechanism integrates with the control unit 106 and adaptive drug release profile system 114 to dynamically adjust delivery parameters. Real-time feedback mechanism 138 ensures optimal and safe treatment delivery.

[00049] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with ai-powered predictive analytics 140, which analyzes historical and real-time data to predict patient responses. This system works with data analytics and reporting system 120 and telehealth integration 116 for proactive treatment adjustments. AI-powered predictive analytics 140 enhances decision-making and improves patient outcomes.

[00050] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with integrated patient education resources 142, which provide information about treatment protocols, side effects, and compliance. These resources are accessible through the user interface 118, improving patient awareness and engagement. Integrated patient education resources 142 support better adherence to prescribed therapies.

[00051] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with enhanced aerosolization techniques 144, which improve the uniformity and efficiency of drug distribution. These techniques integrate with the drug delivery module 104 and administration interface 108 to optimize particle size for targeted delivery. Enhanced aerosolization techniques 144 ensure high treatment efficacy.

[00052] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with cloud-based data storage and analysis 146, which allows treatment data to be stored and accessed remotely. This component works with data analytics and reporting system 120 and telehealth integration 116 for collaborative care and decision-making. Cloud-based data storage and analysis 146 facilitates long-term monitoring and data-driven insights.

[00053] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with multifunctional treatment applications 148, which enable the simultaneous delivery of multiple therapeutic agents. This feature collaborates with the drug delivery module 104 and control unit 106 to manage combined therapies efficiently. Multifunctional treatment applications 148 enhance versatility and patient care.

[00054] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with cross-compatibility with existing medical devices 150, which ensures seamless integration with ventilators, infusion pumps, and other clinical equipment. This compatibility interacts with the modular architecture 124 and telehealth integration 116, enhancing utility and adaptability in various healthcare settings.

[00055] Referring to Fig. 1, gas-based drug administration system for patient treatment 100 is provided with user feedback loop for continuous improvement 152, which collects insights from patients and healthcare providers to refine the system's performance. This feedback loop integrates with data analytics and reporting system 120 and user interface 118 for actionable updates. User feedback loop for continuous improvement 152 drives innovation and system optimization.

[00056] Referring to Fig 2, there is illustrated method 200 for gas-based drug administration system for patient treatment 100. The method comprises:
At step 202, method 200 includes the gas source 102 supplying medical-grade gas into the drug delivery module 104;
At step 204, method 200 includes the drug delivery module 104 formulating and mixing the therapeutic agent with the gas to create a gas-drug mixture;
At step 206, method 200 includes the gas-drug mixture optimization technology 134 dynamically adjusting the ratio of gas to therapeutic agent for maximum efficacy and minimal side effects;
At step 208, method 200 includes the aerosolization technology 110 dispersing the gas-drug mixture into uniformly sized particles for targeted and effective delivery;
At step 210, method 200 includes the control unit 106 regulating the flow rate, dosage, and delivery duration based on programmed parameters;
At step 212, method 200 includes the administration interface 108 delivering the gas-drug mixture to the patient through a mask, nasal cannula, or catheter;
At step 214, method 200 includes the real-time feedback mechanism 138 monitoring patient responses such as oxygen saturation and vital signs during delivery;
At step 216, method 200 includes the adaptive drug release profile system 114 adjusting the delivery rate dynamically based on feedback from the real-time feedback mechanism 138;
At step 218, method 200 includes wearable device connectivity 122 integrating patient vitals and activity data into the system for enhanced personalization;
At step 220, method 200 includes the data analytics and reporting system 120 collecting and analyzing treatment data for healthcare providers;
At step 222, method 200 includes telehealth integration 116 transmitting treatment data to remote healthcare providers for monitoring and adjustments;
At step 224, method 200 includes AI-powered predictive analytics 140 analyzing historical and real-time data to predict patient responses and suggest treatment optimizations;
At step 226, method 200 includes cross-compatibility with existing medical devices 150, such as ventilators and infusion pumps, enabling seamless integration in clinical workflows;
At step 228, method 200 includes emergency override functionality 128 allowing immediate cessation of drug delivery if abnormal conditions are detected;
At step 230, method 200 includes the quality control system 130 ensuring the integrity and consistency of the gas-drug mixture throughout the process;
At step 232, method 200 includes cloud-based data storage and analysis 146 storing treatment records securely for long-term access and collaboration;
At step 234, method 200 includes user feedback loop for continuous improvement 152 collecting insights from patients and healthcare providers to refine system performance and usability.
[00057] The gas-based drug administration system for patient treatment 100 offers numerous benefits and applications across various medical disciplines. By utilizing the gas source 102 and drug delivery module 104, it ensures precise and efficient delivery of therapeutic agents, reducing systemic side effects and improving treatment outcomes. The adaptive drug release profile system 114 and real-time feedback mechanism 138 enable personalized treatment by dynamically adjusting drug delivery based on patient responses, enhancing both efficacy and safety. Its cross-compatibility with existing medical devices 150, such as ventilators and infusion pumps, ensures seamless integration into clinical workflows, while telehealth integration 116 allows remote monitoring and proactive care. Some applications are respiratory therapies, pain management, and localized treatments for chronic diseases or cancer. Additionally, wearable device connectivity 122 enhances patient personalization, and cloud-based data storage and analysis 146 facilitates collaborative decision-making, making the invention versatile, efficient, and revolutionary in modern healthcare.

[00058] In the description of the present invention, it is also to be noted that, unless otherwise explicitly specified or limited, the terms "fixed" "attached" "disposed," "mounted," and "connected" are to be construed broadly, and may for example be fixedly connected, detachably connected, or integrally connected, either mechanically or electrically. They may be connected directly or indirectly through intervening media, or they may be interconnected between two elements. The specific meaning of the above terms in the present invention can be understood in specific cases to those skilled in the art.

[00059] Modifications to embodiments of the present disclosure described in the foregoing are possible without departing from the scope of the present disclosure as defined by the accompanying claims. Expressions such as "including", "comprising", "incorporating", "have", "is" used to describe and claim the present disclosure are intended to be construed in a non- exclusive manner, namely allowing for items, components or elements not explicitly described also to be present. Reference to the singular is also to be construed to relate to the plural where appropriate.

[00060] Although embodiments have been described with reference to a number of illustrative embodiments thereof, it should be understood that numerous other modifications and embodiments can be devised by those skilled in the art that will fall within the spirit and scope of the principles of this disclosure. More particularly, various variations and modifications are possible in the component parts and/or arrangements of the subject combination arrangement within the scope of the present disclosure, the drawings and the appended claims. In addition to variations and modifications in the component parts and/or arrangements, alternative uses will also be apparent to those skilled in the art.
, Claims:WE CLAIM:
1. A gas based drug administration systems for patient treatment 100 comprising of
gas source 102 to supply medical-grade gas for drug delivery;
drug delivery module 104 to mix and formulate the gas-drug mixture;
control unit 106 to regulate dosage, flow rate, and delivery duration;
administration interface 108 to deliver the gas-drug mixture to the patient;
aerosolization technology 110 to disperse the gas-drug mixture into uniform particles;
safety mechanisms 112 to ensure secure operation with pressure regulation and alarms;
adaptive drug release profile system 114 to dynamically adjust the delivery rate;
telehealth integration 116 to enable remote monitoring and adjustments;
user interface 118 to provide an intuitive control platform for users;
data analytics and reporting system 120 to collect and analyze treatment data;
wearable device connectivity 122 to monitor vitals and integrate activity data;
modular architecture 124 to allow for upgrades and customization of the system;
environmentally sustainable features 126 to reduce waste with refillable and biodegradable materials;
emergency override functionality 128 to immediately halt drug delivery if needed;
quality control system 130 to maintain the integrity and consistency of the gas-drug mixture;
patient-specific calibration 132 to tailor dosages to individual patient needs;
gas-drug mixture optimization technology 134 to adjust the ratio of gas to therapeutic agents;
interchangeable administration interfaces 136 to support systemic and localized drug delivery;
real-time feedback mechanism 138 to monitor and respond to patient conditions;
ai-powered predictive analytics 140 to analyze and predict patient treatment responses;
integrated patient education resources 142 to provide treatment information and guidance;
enhanced aerosolization techniques 144 to improve drug distribution efficiency;
cloud-based data storage and analysis 146 to securely store and access treatment data;
multifunctional treatment applications 148 to enable simultaneous delivery of multiple drugs;
cross-compatibility with existing medical devices 150 to integrate seamlessly with clinical workflows; and
user feedback loop for continuous improvement 152 to refine system performance through insights.
2. The gas-based drug administration system for patient treatment 100 as claimed in claim 1, wherein gas source 102 is configured to supply medical-grade gas with precise flow and pressure control, drug delivery module 104 for mixing the therapeutic agent with the gas to create a uniform gas-drug mixture, control unit 106 is programmed to regulate flow rate, dosage, and delivery duration and an administration interface 108 delivers the gas-drug mixture through interchangeable delivery devices, enabling both systemic and localized therapeutic treatments..

3. The gas-based drug administration system for patient treatment 100 as claimed in claim 1, wherein the adaptive drug release profile system 114 is configured to dynamically adjust the drug delivery rate in real time based on patient-specific feedback monitored by the real-time feedback mechanism 138.

4. The gas-based drug administration system for patient treatment 100 as claimed in claim 1, wherein the aerosolization technology 110 disperses the gas-drug mixture into particles of uniform size, ensuring precise targeting and enhanced absorption at the treatment site.

5. The gas-based drug administration system for patient treatment 100 as claimed in claim 1, wherein the telehealth integration 116 enables remote monitoring, real-time adjustments, and data sharing with healthcare providers, improving accessibility and continuity of care.
6. The gas-based drug administration system for patient treatment 100 as claimed in claim 1, wherein the AI-powered predictive analytics 140 analyze historical and real-time data to predict patient responses and optimize treatment parameters dynamically for improved outcomes.

7. The gas-based drug administration system for patient treatment 100 as claimed in claim 1, wherein the emergency override functionality 128 is configured to immediately cease drug delivery during abnormal conditions, ensuring patient safety in critical situations.

8. The gas-based drug administration system for patient treatment 100 as claimed in claim 1, wherein the quality control system 130 continuously monitors the integrity and consistency of the gas-drug mixture to ensure reliability and therapeutic efficacy.

9. The gas-based drug administration system for patient treatment 100 as claimed in claim 1, wherein the modular architecture 124 allows for system upgrades, customization, and compatibility with future medical advancements, ensuring long-term adaptability in diverse clinical applications.

10. The gas-based drug administration system for patient treatment 100 as claimed in claim 1, wherein method comprises of
gas source 102 supplying medical-grade gas into the drug delivery module 104;
drug delivery module 104 formulating and mixing the therapeutic agent with the gas to create a gas-drug mixture;
gas-drug mixture optimization technology 134 dynamically adjusting the ratio of gas to therapeutic agent for maximum efficacy and minimal side effects;
aerosolization technology 110 dispersing the gas-drug mixture into uniformly sized particles for targeted and effective delivery;
control unit 106 regulating the flow rate, dosage, and delivery duration based on programmed parameters;
administration interface 108 delivering the gas-drug mixture to the patient through a mask, nasal cannula, or catheter;
real-time feedback mechanism 138 monitoring patient responses such as oxygen saturation and vital signs during delivery;
adaptive drug release profile system 114 adjusting the delivery rate dynamically based on feedback from the real-time feedback mechanism 138;
wearable device connectivity 122 integrating patient vitals and activity data into the system for enhanced personalization;
data analytics and reporting system 120 collecting and analyzing treatment data for healthcare providers;
telehealth integration 116 transmitting treatment data to remote healthcare providers for monitoring and adjustments;
AI-powered predictive analytics 140 analyzing historical and real-time data to predict patient responses and suggest treatment optimizations;
cross-compatibility with existing medical devices 150, such as ventilators and infusion pumps, enabling seamless integration in clinical workflows;
emergency override functionality 128 allowing immediate cessation of drug delivery if abnormal conditions are detected;
quality control system 130 ensuring the integrity and consistency of the gas-drug mixture throughout the process;
cloud-based data storage and analysis 146 storing treatment records securely for long-term access and collaboration;
user feedback loop for continuous improvement 152 collecting insights from patients and healthcare providers to refine system performance and usability.

Documents